CJC-1295 / Ipamorelin
This IPS-listed option is reviewed privately during consultation. Details are reviewed privately during consultation.
Growth hormone support
A clinician-guided peptide combination used in performance and longevity programs to support natural growth-hormone signaling, recovery, body composition, sleep quality, and healthy-aging goals.
Overview
CJC-1295 and Ipamorelin are commonly discussed together because they support growth-hormone release through complementary signaling pathways. CJC-1295 is related to growth hormone-releasing hormone activity, while Ipamorelin is a selective growth-hormone secretagogue.
IPS evaluates this option in the context of recovery, training demand, sleep, body composition, metabolic health, age, symptoms, and lab markers. It is not a replacement for individualized medical evaluation.
IPS access
This entry comes from the IPS access available list. Final route and candidacy depend on consultation, availability, and clinician judgment.
This IPS-listed option is reviewed privately during consultation. Details are reviewed privately during consultation.
Goals, sleep, training volume, medical history, medications, glucose markers, hormone context, and IGF-1 or related labs may be reviewed.
Often discussed when recovery, sleep, body composition, and healthy-aging goals overlap.
Mechanism
CJC-1295 / Ipamorelin is commonly framed as a dual-pathway growth-hormone support strategy. The goal is to encourage the body's own signaling rather than directly replacing growth hormone.
CJC-1295 is discussed for its relationship to growth hormone-releasing hormone signaling and pituitary GH release.
Ipamorelin is discussed as a selective GH secretagogue that may complement CJC-style signaling.
Growth-hormone signaling can affect IGF-1 pathways, which is why lab context and monitoring may matter.
IPS pairs peptide discussions with sleep, protein, training load, resistance work, hydration, and recovery planning.
Process
Review goals, recovery, sleep, training demand, medical history, medications, and peptide experience.
Labs may be reviewed to understand hormone, metabolic, and safety context before protocol design.
If appropriate, your clinician reviews instructions, timing, expectations, and follow-up cadence.
Follow-up helps evaluate sleep, recovery, body composition, tolerance, and whether the plan should change.
Safety & candidacy
CJC-1295 / Ipamorelin is not appropriate for everyone. IPS reviews health history, relevant labs, cancer history, glucose concerns, medications, pregnancy-related factors where applicable, and individual risk before discussing treatment.
Questions
No. CJC-1295 / Ipamorelin is generally discussed as a secretagogue strategy that supports the body's own signaling rather than direct growth-hormone replacement.
Recovery, sleep quality, body composition, training readiness, vitality, and healthy-aging goals are common reasons patients ask about it.
Labs may be recommended depending on your history, symptoms, goals, and clinician review. IGF-1 and metabolic markers may be relevant in some cases.
Sometimes, but combinations require clinician review so overlapping goals, risks, and monitoring needs are clear.
Contact
Complete the form and IPS will follow up about consultation scheduling and next steps.